Archive for March 2019

Reimbursement of amyloid–positron emission tomography (PET) is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness. The Amyloid Imaging to Prevent Alzheimer’s Disease–Diagnostic and Patient Management Study (AMYPAD-DPMS) is designed to fill this gap.

The Publisher regrets that this article is an accidental duplication of an article that has already been published, DOI of original article: http://dx.doi.org/10.1016/j.jalz.2016.12.004. The duplicate article has therefore been withdrawn.The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal

Several concepts, which in the aggregate get might be used to account for “resilience” against age- and disease-related changes, have been the subject of much research. These include brain reserve, cognitive reserve, and brain maintenance. However, different investigators have use these terms in different ways, and there has never been an attempt to arrive at…

The easily-imaged retinal microvasculature may reflect the brain microvasculature and therefore be related to dementia.

We investigated the proteomic profiles of amyloid plaques (APs) from Alzheimer’s disease (AD) and age-matched non-AD brains and APP/PS1 transgenic model mice.

We examined the relation between self-reported hearing loss, hearing aid use, and risk of subjective cognitive function (SCF) decline.

We read with great interest the article by Lee et al. [1] entitled “Associations between recent and established ophthalmic conditions and risk of Alzheimer’s disease” published recently in Alzheimer’s & Dementia. We are grateful to the authors for sharing their valuable data with the scientific community, and we appreciate their efforts to investigate associations of ocular…

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) separates “early” and “late” mild cognitive impairment (MCI) based on a single memory test. We compared ADNI’s MCI classifications to our neuropsychological approach, which more broadly assesses cognitive abilities.

A small percentage of Alzheimer’s disease (AD) cases are caused by genetic mutations with autosomal dominant inheritance. We report a family with a novel variant in PSEN1.